SELLAS Life Sciences Group, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
SELLAS Life Sciences Group, Inc. (SLS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $0.87 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.87.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.44, a 46.58% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $6.44.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $0.72, a 85.51% decline from fiscal 2024.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $4.97, a 6.20% increase from fiscal 2023.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $4.68, a 24.15% decline from fiscal 2022.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $6.17.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.87 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | $0.87 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $0.72 10-K · filed 2026-03-19 | ||||
| 2024-12-31 | $4.97 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $3.53 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $3.53 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $3.44 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | $4.68 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $5.28 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $5.66 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $6.44 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $6.17 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $2.28 10-Q · filed 2022-11-14 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-14 | ||||
| 2019-12-31 | $175.86 10-K · filed 2021-03-23 | ||||
| 2019-09-30 | $191.05 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $5.24 10-Q · filed 2019-08-14 | ||||
| 2019-03-31 | $5.24 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | $264.77 10-K · filed 2020-03-13 | $5.30 10-K · filed 2019-03-22 | |||
| 2018-09-30 | $5.24 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | $5.24 10-Q · filed 2018-08-14 | ||||
| 2017-12-31 | $52.94 10-K · filed 2018-04-13 | ||||
| 2017-09-30 | $43.01 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $34.21 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | $32.59 10-Q · filed 2017-05-10 | ||||
| 2016-12-31 | $50.28 10-K · filed 2017-03-15 | ||||
| 2016-09-30 | $2.69 10-Q · filed 2016-11-09 | ||||
| 2016-06-30 | $3.07 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $2.37 10-Q · filed 2016-05-10 | ||||
| 2015-12-31 | $2.31 10-K/A · filed 2016-04-15 | ||||
| 2015-09-30 | $2.44 10-Q · filed 2015-11-09 | ||||
| 2015-06-30 | $2.48 10-Q · filed 2015-08-06 | ||||
| 2015-03-31 | $2.71 10-Q · filed 2015-05-07 | ||||
| 2014-12-31 | $2.85 8-K · filed 2015-12-04 | ||||
| 2014-09-30 | $2.42 10-Q · filed 2014-11-05 | ||||
| 2014-06-30 | $2.13 10-Q · filed 2014-08-11 | ||||
| 2014-03-31 | $2.13 10-Q · filed 2014-05-06 | ||||
| 2013-12-31 | $2.80 10-K · filed 2014-03-17 | ||||
| 2013-09-30 | $4.39 10-Q/A · filed 2013-11-07 | ||||
| 2013-06-30 | $4.58 10-Q · filed 2013-08-09 | ||||
| 2013-03-31 | $5.00 10-Q · filed 2013-05-09 | ||||
| 2012-12-31 | $3.52 10-K · filed 2013-03-12 | ||||
| 2012-09-30 | $3.51 10-Q · filed 2012-11-13 | ||||
| 2012-06-30 | $4.84 10-Q · filed 2012-08-14 | ||||
| 2011-12-31 | $4.99 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |